Fenretinide oral - Laurent Pharmaceuticals/McGill University

Drug Profile

Fenretinide oral - Laurent Pharmaceuticals/McGill University

Alternative Names: LAU-7b

Latest Information Update: 23 Mar 2016

Price : $50

At a glance

  • Originator Ortho-McNeil Pharmaceutical
  • Developer Laurent Pharmaceuticals; McGill University
  • Class Antineoplastics; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 17 Mar 2016 Laurent Pharmaceuticals completes a phase Ib trial in Cystic fibrosis in Canada before March 2016 (PO) (NCT02141958)
  • 17 Mar 2016 Laurent Pharmaceuticals plans a phase II trial for Cystic fibrosis in USA and Canada
  • 15 Jun 2015 Interim pharmacokinetics and adverse events data from a phase-Ib trial in Cystic fibrosis released by Laurent Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top